New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
10:23 EDTSWHC, RMTI, MTOR, APOL, NWBO, SBGI, UNXL, ACHN, VRTX, OHRPOptions with decreasing implied volatility
Options with decreasing implied volatility: OHRP VRTX ACHN UNXL SBGI NWBO APOL MTOR RMTI SWHC
News For OHRP;VRTX;ACHN;UNXL;SBGI;NWBO;APOL;MTOR;RMTI;SWHC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 21, 2014
07:34 EDTAPOLApollo Education sees 1Q15 revenue $720M-$730M, consensus $763.70M
Subscribe for More Information
07:33 EDTAPOLApollo Education sees FY15 revenue $2.8B-$2.85B, consensus $2.80B
07:32 EDTAPOLApollo reports Q4 University of Phoenix New Degreed Enrollment down 5.9%
Subscribe for More Information
07:31 EDTAPOLApollo Education reports Q4 EPS from cont. ops. ex-items 34c, consensus 27c
Subscribe for More Information
07:11 EDTVRTXFDA Pulmonary-Allergy Drugs Advisory Committe to hold a meeting
Subscribe for More Information
October 20, 2014
07:25 EDTOHRPOhr Pharmaceutical announces positive data on OHR-102 IMPACT study
Subscribe for More Information
October 17, 2014
15:15 EDTRMTIRockwell Medical volatility elevated
Rockwell Medical November call option implied volatility is at 164, January is at 121, February is at 122; compared to its 26-week average of 76 according to Track Data, suggesting large price movement into a PDUFA Date for Triferic on January 24, 2015.
10:27 EDTVRTXVertex FDA panel expected to be positive at Piper Jaffray
Subscribe for More Information
10:26 EDTVRTXFDA panel asked to consider benefit of Vertex drug in younger CF patients
Subscribe for More Information
10:00 EDTSWHCOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:37 EDTSWHCSmith & Wesson initiated with a Buy at Wunderlich
Subscribe for More Information
October 15, 2014
09:57 EDTACHNLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:07 EDTAPOLFor profit education positive catalysts outweigh negative, says Wells Fargo
Wells Fargo expects for-profit education stocks to benefit from improved hiring trends and a sale by Corinthian of its assets that, according t othe firm ,would set a valuation floor for the sector. The firm continues to believe that the final gainful employment rule will be neutral to positive for the group. Wells favors the option value on the long side for the sector. Publicly traded companies in the space include American Public Education (APEI), Apollo Education (APOL), Bridgepoint Education (BPI), Career Education (CECO), Corinthian Colleges (COCO), DeVry (DV), Grand Canyon (LOPE), ITT Educational (ESI) and Strayer (STRA).
October 14, 2014
13:59 EDTVRTXVertex mentioned cautiously at BofA/Merrill
09:08 EDTNWBONorthwest Biotherapeutics begins first treatment with DCVax-L in Germany
Subscribe for More Information
07:19 EDTOHRPOhr Pharmaceutical announces successful end of Phase II meeting with FDA
Ohr Pharmaceutical announced details of the planned pivotal Phase III registration trials for Squalamine Eye Drops, or OHR-102, in the treatment of wet age-related macular degeneration, or wet AMD. The trials are being designed based on guidance provided by the FDA at a recent "end of Phase II" meeting. The FDA has agreed with Ohr on a 9 month primary efficacy endpoint based on the proportion of patients achieving a greater than or equal to 3 line gain in visual acuity. In the interim analysis of the ongoing Phase II IMPACT study, more than twice the proportion of patients achieved greater than or equal to 3 line gains in visual acuity at 9 months with the combination of OHR-102 eye drops and Lucentis as compared to the Lucentis monotherapy group. Two identical Phase III studies will be performed. The company plans to initiate the Phase III trials in the first half of 2015 with the goal of submitting a New Drug Application following collection and analysis of the 9 month primary efficacy data.
October 13, 2014
10:08 EDTVRTXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:23 EDTVRTXVertex price target raised to $131 from $119 at RW Baird
Subscribe for More Information
06:07 EDTACHNStocks with implied volatility above IV index mean; AVP ACHN
Subscribe for More Information
05:35 EDTVRTXVertex upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Vertex Pharmaceuticals to Overweight citing likely approval of the company's Kalydeco plus lumacaftor combination next year. Piper expects Vertex's Cystic Fibrosis sales to grow to $3.1B in 2016 and raised its price target for shares to $125 from $87.50.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use